Mode
Text Size
Log in / Sign up

Type 2 Diabetes

Part of Diabetes

Subtypes of Type 2 Diabetes

Type 2 Diabetes Mellitus 43

222 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Type 2 Diabetes

346 trials tracked for Type 2 Diabetes: 156 in phase 3 or 4 and 64 with published results. The most-cited published study has 664 citations.

346Trials tracked
156Phase 3 & 4
0Recruiting
64With published results
Phase distribution
Phase 4 62 Phase 3 94 Phase 2 32 Phase 1 14 Other / NA 144
  1. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight Completed · 664 cited
  2. Phase 3 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed · 634 cited
  3. Phase 3 Add-on to Thiazolidinedione (TZD) Failures Completed · 402 cited
  4. Phase 3 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes Completed · 361 cited
  5. Phase 3 A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin Completed · 332 cited
  6. Phase 3 An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets Completed · 313 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM Completed · 267 cited
  2. Phase 4 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed · 263 cited
  3. Phase 3 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes Completed · 254 cited
  4. Phase 4 Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes Completed · 242 cited
  5. Phase 3 A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes Completed · 207 cited
  6. Phase 4 An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Completed · 189 cited
  7. Phase 3 RISE Pediatric Medication Study Completed · 175 cited
  8. Phase 4 Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes Completed · 166 cited
  9. Phase 3 Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 149 cited
  10. Phase 3 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes Completed · 139 cited
  11. Phase 3 A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin Completed · 134 cited
  12. Phase 4 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) Completed · 133 cited
  13. Phase 3 Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients Completed · 130 cited
  14. Phase 4 The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis Completed · 129 cited
  15. Phase 4 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion Completed · 102 cited
  16. Phase 3 Actos Now for Prevention of Diabetes (ACT NOW) Completed · 102 cited
  17. Phase 4 Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency Completed · 100 cited
  18. Phase 4 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling Completed · 97 cited
  19. Phase 3 Vitamin D for Established Type 2 Diabetes (DDM2) Completed · 96 cited
  20. Phase 3 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) Completed · 94 cited
  21. Phase 3 Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes Completed · 85 cited
  22. Phase 3 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years Completed · 84 cited
  23. Phase 4 Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes Completed · 83 cited
  24. Phase 3 A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone Completed · 78 cited
  25. Phase 3 Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Completed · 71 cited
  26. Phase 4 Effects of Metformin on Hepatic FFA Metabolism Completed · 63 cited
  27. Phase 4 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) Completed · 63 cited
  28. Phase 3 Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes Completed · 53 cited
  29. Phase 4 Liraglutide and Peripheral Artery Disease Completed · 52 cited
  30. Phase 4 Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients Completed · 50 cited
  31. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time Completed · 50 cited
  32. Phase 4 Glargine U300 Hospital Trial Completed · 47 cited
  33. Phase 4 Linagliptin's Effect on CD34+ Stem Cells Completed · 46 cited
  34. Phase 4 The Health Influences of Puberty (HIP) Study Completed · 45 cited
  35. Phase 3 RISE Adult Medication Study Completed · 44 cited
  36. Phase 3 Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus Completed · 44 cited
  37. Phase 3 Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients Completed · 38 cited
  38. Phase 4 Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients Completed · 36 cited
  39. Phase 4 Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans Completed · 35 cited
  40. Phase 3 Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) Completed · 32 cited
  41. Phase 4 Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes Completed · 25 cited
  42. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) Completed · 21 cited
  43. Phase 3 A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin Completed · 17 cited
  44. Phase 3 A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes Completed · 17 cited

Showing the 50 most-cited and recently-updated of 346 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Type 2 Diabetes: what the trials found

Orforglipron significantly reduced HbA1c from baseline (p < 0.001) and increased the proportion of patients achieving target HbA1c levels of both <7.0% and ≤6.5% (p < 0.001).

Subgingival chlorhexidine irrigation was associated with a statistically significant improvement in systemic health as measured by HbA1c when correlated with changes in oral probing depth (p = 0.0378), though it did not show a significant association with flow-mediated dilation.

Omega-3 fatty acids (fish oil) were associated with improvements in the OGTT index of insulin sensitivity and varied results for beta-cell function.

Glimepiride, when added to metformin, demonstrated specific outcomes regarding time to reach HbA1c thresholds of 7% or 7.5%.

Recent results — preliminary, needs further review

  • T2.coach was associated with a significant reduction in mean HbA1c values (p = 0.0085).
  • Medical weight loss resulted in reductions in body weight and HbA1c, with some participants achieving diabetes remission.
  • A CGM-based titration algorithm significantly increased time in range (p = 0.001) and was associated with a reduction in HbA1c.
  • Multi-caregiving interventions were associated with mean reductions in HbA1c of approximately 0.53% to 0.57%.
  • The DyaMX device was associated with post-procedure HbA1c values ranging from 7.7% to 8.8% and fasting plasma glucose levels decreasing over follow-up visits.

For the clinician treating this condition

  • Orforglipron is an effective pharmacological option for reducing HbA1c and achieving clinical targets.
  • Oral health interventions, specifically subgingival chlorhexidine irrigation, may have a measurable impact on systemic HbA1c levels.
  • Weight loss programs and specific digital/mobile interventions (e.g., T2.coach) are associated with significant reductions in HbA1c.
  • Advanced monitoring technologies, such as CGM-based titration algorithms, significantly improve time in range.

AI synthesis of 0 cited trials, updated Jun 15, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Type 2 Diabetes: current evidence & treatments

Multiple pharmacological interventions show efficacy in type 2 diabetes management. SGLT2 inhibitors reduce all-cause mortality in heart transplant recipients 1 and provide robust prognostic benefits in heart failure 4, but increase diabetic ketoacidosis risk, especially with elevated HbA1c 22. GLP-1 receptor agonists may reduce cognitive decline 8 and show no increased ocular disorder risk 17, while semaglutide reduces kidney decline or death in chronic kidney disease 6. Metformin is associated with higher lactate concentrations during exercise 5, and paternal use shows no increased risk of major congenital malformations 23. Thiazolidinediones show lower hepatocellular carcinoma risk compared to other classes 21, and GLP-1RAs show lower risk of serious liver events versus DPP-4 inhibitors 18.

Lifestyle and behavioral interventions are effective. Resistance training reduces HbA1c by 0.62% and systolic blood pressure by 3.91 mmHg 24. Multicomponent behavioral interventions achieve sustained HbA1c reduction of 1.84% at 12-36 months 25. Eating later in the biological day is associated with impaired glucose regulation 14. Real-time continuous glucose monitoring improves HbA1c versus self-monitoring 19. Metabolic subtypes identify Japanese adults with prediabetes at different T2D risk 13. Preoperative comorbidities like type 2 diabetes are linked to reduced weight loss after bariatric surgery 7.

Genetic and molecular studies reveal insights into diabetes pathophysiology. Transcriptomic analysis identifies 337 high-confidence T2D-associated genes in pancreatic islets 3. A multi-ancestry meta-analysis identifies 37 loci linked to gestational diabetes, 7 novel 15. AI-driven cardiovascular risk prediction shows promise but bias and lack of diversity limit clinical use 16. Case reports highlight rare adverse effects: voglibose may cause leukopenia 10, and single-incision sleeve plus bypass shows short-term safety in 3 patients 2.

Key drugs in the evidence

semaglutide 22 dapagliflozin 14 metformin 13 SGLT2 inhibitors 13 GLP-1 receptor agonists 11 tirzepatide 6 liraglutide 5 insulin 5 placebo 5 glucagon-like peptide-1 receptor agonists 5

Latest findings

AI-generated synthesis of 21 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Diabetes

Related studies from across the Diabetes family.

A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Diabetes & Endocrinology Guideline
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes
Physical Medicine & Rehab Meta-analysis
Evaluating the Impact of Digital Health Interventions on Chronic Disease Self-Care Outcomes Digital health tools show mixed results for managing chronic diseases
Digital tools show promise for heart failure monitoring but lack consistent evidence for improving medication adherence or general diabetes …
New data shows that while digital tools like apps can help heart failure patients monitor their health, they may not improve medication habi…
Pharmacist-led telepharmacy may improve medication adherence and reduce blood pressure in patients with NCDs
Cardiology Sys. Review
Pharmacist-led telepharmacy may improve medication adherence and reduce blood pressure in patients with NCDs Pharmacist Led Telepharmacy May Improve Medication Adherence For Chronic Illness
This systematic review analyzed 21 trials involving 5440 participants to evaluate pharmacist-led telepharmacy for managing non-communicable …
Remote pharmacist services through phone or video may help patients with high blood pressure and diabetes stick to their daily medication pl…
Pancreatic cancer involves multilayered mechanisms from environment to immune escape
Diabetes & Endocrinology Sys. Review
Pancreatic cancer involves multilayered mechanisms from environment to immune escape Review reveals complex causes of pancreatic cancer
This narrative review synthesizes the multilayered mechanisms of pancreatic cancer, including environmental exposure, genetic susceptibility…
Pancreatic cancer arises from a mix of genetics, lifestyle, and inflammation, review finds.
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
Drug Pipeline Guideline
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes
Diabetes & Endocrinology Meta-analysis
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes High rates of diabetes complications found in adult Ugandans
This meta-analysis examined the prevalence of various diabetic complications, including neuropathy and retinopathy, in a large cohort of adu…
More than half of Ugandan adults with diabetes suffer from nerve damage, highlighting a critical need for earlier screening and better care.
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy
Neurology Sys. Review
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy New research explores how inflammation drives nerve damage in diabetes
This narrative review explores the pathophysiology of diabetic peripheral neuropathy, focusing on how hyperglycemia, lipotoxicity, and intes…
Chronic high blood sugar causes more than just high glucose; it triggers a cycle of inflammation and immune stress that damages nerves.
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems
Diabetes & Endocrinology Sys. Review
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems Understanding how high blood sugar damages the entire nervous system in diabetes
This narrative review synthesizes how chronic hyperglycemia impacts the entire neuroaxis in patients with diabetes. It details metabolic and…
High blood sugar can damage nerves throughout the whole body. This affects your senses, movement, and internal organs.
Pancreatic tissue engineering faces vascularization hurdle in type 1 diabetes therapy
Diabetes & Endocrinology Sys. Review
Pancreatic tissue engineering faces vascularization hurdle in type 1 diabetes therapy New tissue engineering methods aim to improve pancreatic transplants
This narrative review examines pancreatic tissue engineering for type 1 diabetes, highlighting insufficient vascularization as the dominant …
Current pancreas transplants are limited by a shortage of donors and the need for lifelong drugs. New engineering techniques may offer a dif…
CAR technology for autoimmune disorders, infectious diseases, fibrotic lesions, inflammatory bowel disease, and type 1 diabetes is reviewed
Allergy & Immunology Sys. Review
CAR technology for autoimmune disorders, infectious diseases, fibrotic lesions, inflammatory bowel disease, and type 1 diabetes is reviewed Chimeric antigen receptor technology may help treat autoimmune disorders and other conditions
This narrative review discusses the application of chimeric antigen receptor (CAR) technology across autoimmune disorders, infectious diseas…
A narrative review suggests chimeric antigen receptor technology could be useful for treating autoimmune disorders, infectious diseases, and…
HIV linked to lower odds of post-TB lung disease; undernutrition raises risk
Infectious Disease Meta-analysis
HIV linked to lower odds of post-TB lung disease; undernutrition raises risk Undernutrition and HIV may lower or raise lung damage risk after tuberculosis in low-income nations
This systematic review and meta-analysis of 41 studies in LMICs found that HIV was associated with reduced odds of spirometry-defined post-t…
New analysis of data from low-income countries shows mixed results on how HIV, diabetes, and poor nutrition affect lung health after tubercu…
scFv-based biologics show potential for immunomodulation in type 1 and type 2 diabetes
Allergy & Immunology Sys. Review
scFv-based biologics show potential for immunomodulation in type 1 and type 2 diabetes Review explores scFv biologics for Type 1 and Type 2 diabetes care
This narrative review explores the potential of single-chain variable fragment (scFv)-based biologics for treating type 1 and type 2 diabete…
This review looks at scFv-based biologics for diabetes. It discusses how these treatments might help with immune control and blood sugar bal…

Questions about Type 2 Diabetes

What common genes link Polycystic Ovary Syndrome and type 2 diabetes according to recent studies?

Recent studies link PCOS and type 2 diabetes through shared genetic variants, notably the insulin gene VNTR and epigenetic changes in metabolism-related genes.

Full answer →
What are the standard treatment options available for someone with Type 2 Diabetes?

Standard treatment for type 2 diabetes includes lifestyle changes (diet, exercise), metformin, other medications like GLP-1 agonists (e.g., semaglutide, tirzepatide), and sometimes insulin, along with monitoring blood sugar and managing cardiovascular risk.

Full answer →
What are the best lifestyle changes to manage Type 2 Diabetes effectively?

A Mediterranean diet, regular physical activity, weight loss, and digital health tools can effectively manage type 2 diabetes, with medication support as needed.

Full answer →